An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.
An expert in the management of heart failure provides an overview of the progressive nature of the disease, with special consideration to biomarker monitorization.
June 11th 2021, 11:00am
Patients with obstructive hypertrophic cardiomyopathy (HCM) use significant health care resources, and mavacamten can help to reduce their symptoms and improve their function, noted Jay Edelberg, MD, PhD, head of Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb.
June 8th 2021, 6:41pm
Progressive rehabilitation produced superior results among patients randomized to a 36-session program during or following hospitalization for acute decompensated heart failure vs those randomized to usual care.
June 5th 2021, 11:30am
Barriers to authorship and adequate representation of women in heart failure–focused clinical trials need to be addressed, noted Mariana Garcia, MD, cardiology fellow in the Academic Clinical Investigator Pathway at Emory University and member of T32, Multidisciplinary Research Training to Reduce Inequalities in Cardiovascular Health (METRIC).
June 2nd 2021, 6:48pm
Data from the DAPA-HF trial and published literature show intermediate-level cost-effectiveness of dapagliflozin use among patients with heart failure with reduced ejection fraction (HFrEF).
May 28th 2021, 12:00pm
The increase in hospitalization risk seen with Vascepa was small vs the survival gains seen from decreased rates of heart attack, stroke, and revascularization, noted Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center.
May 24th 2021, 6:00pm
Mount Sinai research released today shows a possible link between excess pericardial fat and greater risk of heart failure, with implications for early intervention and prevention of heart disease.
May 21st 2021, 5:00pm
The latest coverage in the heart failure space from across MJH Life Sciences™.
May 18th 2021, 4:10pm
We want to use artificial intelligence (AI) to promote the best-case scenario in patient care, emphasized James Januzzi, MD, staff cardiologist at Massachusetts General Hospital.
May 15th 2021, 12:30pm
Rates of acute heart failure (AHF) have recently been rapidly increasing among elderly and super-elderly patients in Japan, and this study investigated rates of all-cause death and mode of death among this patient population.
May 14th 2021, 1:00pm
These 4 studies were pegged as “ones to watch” during the American College of Cardiology (ACC) annual briefing on results for consumers. They will be presented in the opening session of late-breaking clinical trial results on day 1 of ACC.21.
